Analysen von James Gordon
| 05.07.22 | GSK Neutral | JP Morgan Chase & Co. | |
| 29.06.22 | GSK Neutral | JP Morgan Chase & Co. | |
| 15.06.22 | MorphoSys Neutral | JP Morgan Chase & Co. | |
| 10.06.22 | GSK Neutral | JP Morgan Chase & Co. | |
| 07.06.22 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 06.06.22 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 06.06.22 | GSK Neutral | JP Morgan Chase & Co. | |
| 31.05.22 | GSK Neutral | JP Morgan Chase & Co. | |
|
Werbung
|
|||
| 25.05.22 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 13.05.22 | MorphoSys Neutral | JP Morgan Chase & Co. | |
| 13.05.22 | GSK Neutral | JP Morgan Chase & Co. | |
| 11.05.22 | MorphoSys Neutral | JP Morgan Chase & Co. | |
| 05.05.22 | MorphoSys Neutral | JP Morgan Chase & Co. | |
| 03.05.22 | MorphoSys Neutral | JP Morgan Chase & Co. | |
| 29.04.22 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 28.04.22 | GSK Neutral | JP Morgan Chase & Co. | |
| 27.04.22 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 13.04.22 | GSK Neutral | JP Morgan Chase & Co. | |
| 11.04.22 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 07.04.22 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 05.04.22 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 01.04.22 | GSK Neutral | JP Morgan Chase & Co. | |
| 21.03.22 | MorphoSys Neutral | JP Morgan Chase & Co. | |
| 17.03.22 | MorphoSys Neutral | JP Morgan Chase & Co. | |
| 28.02.22 | GSK Neutral | JP Morgan Chase & Co. | |
| 23.02.22 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 21.02.22 | GSK Neutral | JP Morgan Chase & Co. | |
| 18.02.22 | GSK Neutral | JP Morgan Chase & Co. | |
| 15.02.22 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 09.02.22 | GSK Neutral | JP Morgan Chase & Co. | |
| 02.02.22 | GSK Neutral | JP Morgan Chase & Co. | |
| 25.01.22 | GSK Neutral | JP Morgan Chase & Co. | |
| 19.01.22 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 17.01.22 | GSK Neutral | JP Morgan Chase & Co. | |
| 17.01.22 | MorphoSys Neutral | JP Morgan Chase & Co. | |
| 13.01.22 | GSK Neutral | JP Morgan Chase & Co. | |
| 10.01.22 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 07.01.22 | MorphoSys Neutral | JP Morgan Chase & Co. | |
| 12.11.21 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 11.11.21 | MorphoSys Neutral | JP Morgan Chase & Co. | |
| 08.11.21 | GSK Neutral | JP Morgan Chase & Co. | |
| 01.11.21 | MorphoSys Neutral | JP Morgan Chase & Co. | |
| 01.11.21 | GSK Neutral | JP Morgan Chase & Co. | |
| 27.10.21 | GSK Neutral | JP Morgan Chase & Co. | |
| 25.10.21 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 21.10.21 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 18.10.21 | GSK Neutral | JP Morgan Chase & Co. | |
| 15.10.21 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 13.10.21 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 06.10.21 | MorphoSys Neutral | JP Morgan Chase & Co. | |